All articles by Andrew Turley
-
FeatureThe dream of zeolite design
Zeolites are important industrial catalysts, so why can’t chemists make them to order? Andrew Turley finds out
-
PodcastCitric acid
If life hands you lemons, make lemonade – or you could make citric acid, a very useful commodity chemical according to Andrew Turley
-
-
ResearchCarbon nanotube-based sensor detects meat spoilage
Electron density of cobalt porphyrin complexes key to meat freshness sensor
-
Business23andMe jumps into drug R&D
Gene profiling firm aims to capitalise on its databank of genetic information to discover new drugs
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
BusinessHepatitis C drug patent challenged in Europe
Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent
-
ResearchFish skin dressing helps heal wounds
Collagen fibres derived from the skin of tilapia fish supported faster wound healing in rats
-
ResearchEnzyme uses internal network for cyclisation
Researchers have pinpointed individual amino acid residues involved in the production of cyclic terpenes by a plant enzyme
-
-
Business
DuPont and Monsanto settle Roundup dispute
Firms drop expensive ongoing litigation in favour of a licensing deal
-
Business
Interpol teams up with pharma
Pharmaceutical crime programme will seek to reduce trade in fake drugs
-
Business
Dow makes $1.5bn divestiture plans
Liveris in favour of ‘selectively pruning’ further non-core units
-
Business
Dispute over Arkema finances
French speciality chemical company Arkema accused of misrepresenting business sold to investment firm last year
-
Business
Alcohol dependence pill approved in EU
Selincro tablets from Lundbeck designed to reduce consumption of alcohol
-
Business
University to acquire Shell UK R&D site
Site at Thornton will become a science park under the stewardship of the University of Chester
-
Business
Dow rapped for $1bn tax scheme
Judge opines: ‘tax law deals in economic realities, not legal abstractions’
-
Business
Does chemical regulation boost innovation?
Report suggests that supply of innovation responds to extra demand created by new laws
-
Business
Talk of a $6.6bn deal for Elan
Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights
-
Business
$595m octreotide deal grabs Roche
Company will get worldwide rights to oral formulation of growth hormone drug